ARQT

Arcutis Biotherapeutics, Inc. (ARQT) Economic Moat Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Profitability Returns

Gross margin remains exceptionally high at 91.1%, supporting strong product economics.

Return on invested capital is 10.0% and return on equity is 15.1%, indicating acceptable but not elite capital efficiency.

Operating margin is 7.4% and net margin is 6.1%, showing the business is profitable but not yet highly scaled.

Balance Sheet Resilience

Liquidity is solid with a current ratio of 2.9 and quick ratio of 2.7.

Leverage remains manageable with debt-to-equity at 0.52 and net debt to EBITDA at 1.8.

Interest coverage of 2.5x suggests the company can service debt, but not with a wide margin of safety.

Cash Generation Quality

Free cash flow conversion is strong, with free cash flow nearly matching operating cash flow.

Operating cash flow margin is 8.5%, indicating cash generation is positive but not yet robust relative to sales.

Cash conversion remains pressured by a long operating cycle and cash conversion cycle, reflecting working-capital intensity.

Competitive Positioning

High gross margins suggest some pricing power or differentiated product economics.

However, the company’s moat is not yet clearly proven by consistently high returns on capital or durable operating leverage.

The business still appears in a build-out phase, with profitability improving but not yet demonstrating a wide economic moat.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Arcutis Biotherapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →